Literature DB >> 30001822

Perceived advantages and disadvantages of oral anticoagulants, and the trade-offs patients make in choosing anticoagulant therapy and adhering to their drug regimen.

Melissa C W Vaanholt1, Marieke G M Weernink2, Clemens von Birgelen3, Catharina G M Groothuis-Oudshoorn4, Maarten J IJzerman5, Janine A van Til6.   

Abstract

OBJECTIVE: The objective of this study was to explore the perceived advantages and disadvantages of oral anticoagulant therapies (OAT), and the trade-offs patients make in choosing therapy and adhering to their drug regimen.
METHODS: Five focus group sessions were conducted across Europe among patients with atrial fibrillation to identify the most important factors impacting OAT's value and adherence.
RESULTS: The most frequently identified barriers to OAT were lack of knowledge; poor patient-physician relationships; distraction due to employment or social environment; prior bleeding event(s) or the fear of bleeding; and changes in routine. Factors identified as promoting adherence included patients' personality, motivation, attitudes, and medication-taking habits and routines, as well as good quality health services. Inconvenient aspects of vitamin-K antagonists, such as regular blood monitoring and diet restrictions, were not reported to influence adherence, but may trigger patients to switch to direct oral anticoagulants.
CONCLUSION: Most patients reported that a mixture of modifiable and non-modifiable factors helps them to take their drugs as prescribed. Individual patients' particular needs and preferences regarding OAT vary. PRACTICE IMPLICATIONS: OAT adherence can be promoted if therapies are tailored to patients' needs and preferences. Patients should be supported to share their preferences with their clinician.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adherence; Anticoagulation; Atrial fibrillation; Focus group; Patient perspective; Stroke; Values

Mesh:

Substances:

Year:  2018        PMID: 30001822     DOI: 10.1016/j.pec.2018.06.019

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  6 in total

1.  Heterogeneity in Preferences for Anti-coagulant Use in Atrial Fibrillation: A Latent Class Analysis.

Authors:  Janine van Til; Catharina Oudshoorn-Groothuis; Marieke Weernink; Clemens von Birgelen
Journal:  Patient       Date:  2020-08       Impact factor: 3.883

2.  Patients' Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis.

Authors:  Marieke G M Weernink; Melissa C W Vaanholt; Catharina G M Groothuis-Oudshoorn; Clemens von Birgelen; Maarten J IJzerman; Janine A van Til
Journal:  Am J Cardiovasc Drugs       Date:  2018-12       Impact factor: 3.571

3.  Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review.

Authors:  Eveline M Bunge; Ben van Hout; Sylvia Haas; Georgios Spentzouris; Alexander Cohen
Journal:  BMJ Open       Date:  2021-02-01       Impact factor: 2.692

4.  Development of a New Patient-Reported Medication Adherence Instrument: Concerns Influencing Medication Adherence.

Authors:  Sonal Ghura Mansukhani; Elizabeth A MacLean; Laura L Manzey; Carl J Possidente; Joseph C Cappelleri; Linda S Deal
Journal:  Patient Prefer Adherence       Date:  2021-09-09       Impact factor: 2.711

5.  Qualitative study of willingness and demand for participation in decision-making regarding anticoagulation therapy in patient undergoing heart valve replacement.

Authors:  YaNing Zang; ShanShan Liu; YuHong Chen
Journal:  BMC Med Inform Decis Mak       Date:  2022-02-18       Impact factor: 2.796

6.  Reasons for discontinuing oral anticoagulation therapy for atrial fibrillation: a systematic review.

Authors:  Jackie Buck; Julia Fromings Hill; Alison Martin; Cassandra Springate; Bikramaditya Ghosh; Rachel Ashton; Gerry Lee; Andrzei Orlowski
Journal:  Age Ageing       Date:  2021-06-28       Impact factor: 10.668

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.